The Oncology Institute, Inc.
TOINASDAQHealthcare● Active
$5.07
+$0.20(+4.11%)
Market Cap$506913303
P/E Ratio—
52W High$5.575
52W Low$2.015
The Oncology Institute, Inc. (TOI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TOI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.50B | $0.39B | $0.32B | $0.25B | $0.20B |
| Cost of Revenue | $0.43B | $0.34B | $0.26B | $0.20B | $0.16B |
| Gross Profit | $0.08B | $0.05B | $0.06B | $0.05B | $0.04B |
| Gross Margin %(computed) | 15.20% | 13.73% | 18.37% | 20.63% | 20.12% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.11B | $0.11B | $0.14B | $0.13B | $0.09B |
| Operating Income | ($0.04B) | ($0.06B) | ($0.08B) | ($0.08B) | ($0.05B) |
| Operating Margin %(computed) | -7.18% | -15.28% | -23.75% | -32.46% | -22.59% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | ($0.06B) | ($0.06B) | ($0.08B) | ($0.00B) | ($0.01B) |
| Income Tax Expense | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Income | ($0.06B) | ($0.06B) | ($0.08B) | $0.00B | ($0.01B) |
| Net Margin %(computed) | -12.06% | -16.44% | -25.62% | 0.06% | -5.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.54 | $-0.71 | $-0.92 | $0.00 | $-0.16 |
| Wtd Avg Shares | 0.92B | 0.08B | 0.07B | 0.07B | 0.07B |
| EBITDA | ($0.04B) | ($0.05B) | ($0.05B) | ($0.07B) | ($0.04B) |
| EBITDA Margin %(computed) | -8.46% | -13.68% | -16.74% | -26.77% | -20.71% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more The Oncology Institute, Inc. data
About The Oncology Institute, Inc. (TOI) Income Statement
The Oncology Institute, Inc. (TOI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TOI reported revenue of $0.50B, gross profit of $0.08B (gross margin 15.20%), and net income of ($0.06B) — a net profit margin of -12.06%.
Frequently asked questions
TOI · 4 questionsThe Oncology Institute, Inc. (TOI) reported revenue of $0.50B for 2025, up 27.8% year-over-year.
TOI revenueTOI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08